This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): infliximab, Avakine, TA-650
Description: Remicade is a chimeric monoclonal antibody, with human constant and murine variable regions, that binds to TNF-alpha. Infliximab neutralizes the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibits binding of TNF-alpha with its receptors.
Deal Structure: Remicade was developed by Centocor, which is now a subsidiary of Johnson & Johnson. Schering-Plough markets Remicade in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku markets the product (licensed in 1993) and in China where Xian-Janssen markets Remicade.
Mitsubishi and Tanabe Seiyaku
In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.
Schering-Plough and Centocor
In December 2007, Centocor and SGP revised their 1998 distribution agreement regarding the development, commercialization and distribution of both Remicade and golimumab. Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough's rights to exclusively market Remicade in its current marketing territories outside the United States beyond 2014 to match the current duration of its...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation DRI Capital Inc.
Additional information available to subscribers only: